Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

The Current Application Prospects of Nanomedicine in Renal Ischemia-Reperfusion Injury

Jiang C., Liu C., He X., Guo Y., Zhang J.

Narrative Review on Acute Kidney Injury, Chronic Inflammation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Nanomedicine (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42368402
PMCID
PMC13295006
DOI
10.2147/ijn.s612146

Abstract (original English)

Renal ischemia-reperfusion injury (RIRI) is one of the main causes of acute kidney injury (AKI), and its pathological mechanism is complex, mainly involving multiple pathological processes such as oxidative stress outbreak, uncontrolled inflammatory response, abnormal cell apoptosis, and microcirculatory disorders. Currently, there is a lack of efficient and accurate diagnosis and treatment strategies in clinical practice. As a cross discipline integrating nanomaterials, medicine and biology, nanomedicine has shown unique advantages and broad application prospects in the diagnosis and treatment field of RIRI in recent years. Its core carriers include inorganic nanoparticles, polymeric nanoparticles, nanoenzymes, extracellular vesicles, cell membrane camouflage nanoparticles and injectable nanohydrogels. The diagnosis and treatment system based on nanomedicine can breakthrough the limitations of traditional diagnosis and treatment models, and play an important role in early accurate diagnosis, targeted drug delivery, precise treatment of lesion sites, and prolonged drug circulation time in RIRI. It effectively solves pain points such as strong toxicity, short circulation time, and poor targeting of single drugs. However, the specific mechanism of action of nanomedicine in RIRI has not been fully elucidated, and issues such as the biosafety, in vivo metabolic patterns, and clinic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
KidneyAnimalsHumansReperfusion InjuryNanomedicineNanoparticlesAcute Kidney Injury

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research